AlgoTherapeutix Completes Phase I for Peripheral Neuropathy Program ATX01, Poised for Phase II Initiation in 2022
17.11.2021 12:02:00 EET | Business Wire | Press release
France-based biotechnology company AlgoTherapeutix, developer of ATX01, an innovative topical treatment for the pain of peripheral neuropathy, announced today that the ATX01 Phase I trial successfully reached its safety and pharmacokinetics objectives, clearing the way for Phase II development in Chemotherapy-Induced Peripheral Neuropathy (CIPN).
Stéphane Thiroloix, Founder & CEO of AlgoTherapeutix, comments : “The outcome of this Phase I trial is an important milestone for AlgoTherapeutix. We are delighted that ATX01’s innovative approach and formulation did not raise any safety concern, and its PK profile is consistent with our objectives. We are now busy preparing for the pivotal Phase II CIPN study.”
Over half of cancer patients treated with chemotherapy - over two million patients in the US and Europe - develop CIPN and experience sensory symptoms and pain in the feet and hands: loss of sensitivity, tingling, burning, cold and intense pain can persist for months to years after treatment. CIPN is a leading cause of modification or interruption of chemotherapy. To this date, no therapeutic approach has offered a satisfactory response for patients and their caregivers, oncologists and pain specialists.
A recent publication in the “Journal of Pain” describes the exploratory pharmacological impact of high-dose topical amitriptyline in CIPN patients along with the mechanism of action supporting its activity (https://doi.org/10.1016/j.jpain.2020.11.002)
About AlgoTherapeutix : AlgoTherapeutix is a French biotech founded in 2018 to develop innovative solutions for complex pain. In 2020, AlgoTherapeutix raised a 12 M€ Series A led by Bpifrance and Omnes Capital to move its lead program ATX01 into clinical development. ATX01 is Phase II ready in painful peripheral neuropathy.
More information on AlgoTherapeutix : www.algotx.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211117005624/en/
Contact information
Contact AlgoTherapeutix :
AlgoTherapeutix SAS
49 rue des Nouvelles - 92150 Suresnes
contact@algotx.com
Press contact :
Geneviève Cliquet Consultant
T: +33(0) 607 500 567
contact@cliquet-consultant.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IAMPHENOM Europe 2026 Registration Opens: HR’s Leading Conference for Agentic AI Learning Returns20.5.2026 14:00:00 EEST | Press release
Phenom, the leader in applied AI with an infrastructure built specifically to redesign work operations, today announced registration is open for IAMPHENOM Europe 2026, taking place 4-5 November in Paris, France. The only applied AI event dedicated to human resources on the continent, IAMPHENOM Europe gives HR and HRIT leaders the agentic AI strategies, instruction and proof points they need to build their AI-augmented workforce to address their biggest hiring, development and retention challenges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520683492/en/ Phenom today announced registration is open for IAMPHENOM Europe 2026. The only applied AI event dedicated to human resources on the continent is taking place 4-5 November in Paris, France. European organisations face pressure from every direction, including widening skills shortages, tightening EU AI Act compliance and competitors moving faster with AI than HR teams c
BeOne Medicines Launches One Save Changes Everything, a Global Cancer Care Awareness Campaign with Soccer Legend Tim Howard20.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today launched One Save Changes Everything, a campaign that uses soccer as a lens to recognize the scientific, clinical, and human moments that matter in cancer care. The campaign launches with goalkeeping legends, including former U.S. Men’s National Team goalkeeper Tim Howard. The initiative is backed by a $300,000 community commitment for the installation of soccer mini-pitches near cancer treatment centers with the U.S. Soccer Foundation, and BeOne colleague‑driven charitable support across the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520118614/en/ BeOne Medicines' One Save Changes Everything campaign uses soccer as a lens to recognize the scientific, clinical, and human moments that matter in cancer care. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne Medicines, said: “Just like soccer is defined by sa
Chiesi Group Announces New Chair and Vice Chair20.5.2026 12:00:00 EEST | Press release
Chiesi today announced a planned leadership change in its Board of Directors: Maria Paola Chiesi has been appointed Chair of the Board, succeeding Alessandro Chiesi, who is completing his tenure after nearly three years in the role, and will now continue to serve as Vice Chair. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520447292/en/ Maria Paola Chiesi is appointed Chair of Chiesi Board of Directors, the first woman in this role; aims to reinforce sustainability as an integral and enduring pillar of the Group’s strategy During his mandate, Alessandro Chiesi oversaw the Group through a phase of continued international development and governance strengthening, thereby further consolidating Chiesi’s long-term strategy as a research focused biopharmaceutical company and certified B Corp. “It has been my privilege to serve as Chair during a period of evolution for Chiesi,” said Alessandro Chiesi. “What has remained unchang
Insurance Investment Outsourcing Surpasses $5.5 Trillion as Private Markets and Global Expansion Reshape the Industry20.5.2026 10:00:00 EEST | Press release
Clearwater Analytics (NYSE: CWAN) today released the 2026 Insurance Investment Outsourcing Report (IIOR), produced in partnership with DCS Financial Consulting. The report captures $5.5 trillion in third-party general account insurance assets under management across 96 asset managers, a 23% increase year-over-year and a 65% increase since 2021, alongside $1.8 trillion in assets under advisement across 12 investment consultants. The findings point to an outsourcing market that has become larger, more global, and materially more complex. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520780028/en/ The 2026 IIOR reveals defining trends reshaping insurance investment management: Private Markets Cross a Threshold. Third-party private insurance AUM has more than doubled since 2021, reaching $947 billion and approaching one-third of outsourced insurance allocations alongside public assets. Insurers have moved steadily beyond tra
Factbird Adds Quality & Compliance and Reports to its Manufacturing Intelligence Platform20.5.2026 09:00:00 EEST | Press release
Today, Factbird is announcing two major additions to its manufacturing intelligence platform: Quality & Compliance and Factbird Reports. Both address a problem that compounds as manufacturers grow. More sites mean more variation in how work gets done. More regulation means more documentation pressure on frontline teams. And more data, when fragmented across systems, often slows decisions rather than speeding them up. Solving this has traditionally meant large IT projects and months of deployment. “Enterprise manufacturers shouldn’t have to choose between capability and simplicity,” said Mogens Arne Hansen, Chief Technology and Product Officerat Factbird. “With Quality & Compliance and Reports, you can have standardized, audit-ready operations and automated performance reporting across every site, deployed in days, used by the people on the floor.” Quality & Compliance: standardized, compliant operations across every site Regulated manufacturers in food and beverage, pharma, and medical
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom